drugset

drugset / Trial / NCT00324194

A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

NCT00324194 ↗

Phase 1 Completed 25 enrolled Mirati Therapeutics Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

In this study, MGCD0103, a new anticancer drug under investigation, is given twice weekly to patients with leukemia or myelodysplastic syndromes.

Timeline

Start: 2005-02
Primary completion: 2008-03
Completion: 2008-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mocetinostat	Small molecule	—	Oral

Indications